Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
225.60-0.52 (-0.23%)
As of 10:53AM EST. Market open.
| Previous close | 226.12 |
| Open | 226.59 |
| Bid | 225.56 x 1200 |
| Ask | 225.80 x 800 |
| Day's range | 224.75 - 227.44 |
| 52-week range | 197.47 - 306.08 |
| Volume | 486,105 |
| Avg. volume | 2,229,250 |
| Market cap | 58.665B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 22.11 |
| EPS (TTM) | 10.20 |
| Earnings date | 28 Jan 2021 - 01 Feb 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 285.58 |
- Zacks
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals
- Motley Fool
The Top 3 Biotech Stocks to Buy in 2021
Last year, companies working on coronavirus vaccines led gains in biotech stocks. Considering these elements, here are my top biotech stocks to buy in 2021. Moderna (NASDAQ: MRNA) shares climbed more than 430% last year.
- Motley Fool
3 Top Biotech Picks for 2021
If you want sizzling returns, look no further than the biotech industry. The SPDR S&P Biotech ETF (NYSEMKT: XBI) -- a pretty good barometer for biotechs -- delivered a 48% gain last year. That marked the best performance for the ETF since 2013, when it soared by roughly the same amount.
© 2021 Verizon Media. All rights reserved.
